Form 4 for KALA KALA BIO, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-06 · accession 0001415889-25-001063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-07 | 2025-01-06 | KALA | Kharabi Darius | Chief BUSINESS Off | S - Sale | $7.63 | -2,021 | 67.8K | -3% | -$15.4K |
| D | 2025-01-07 | 2025-01-06 | KALA | Kharabi Darius | Chief BUSINESS Off | A - Grant | $0.00 | +10.1K | 69.8K | +17% | $0 |
| D | 2025-01-07 | 2025-01-06 | KALA | Kharabi Darius | Chief BUSINESS Off | A - Grant | $0.00 | +45.2K | 45.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | S | D | 2,021 | $7.63 | 67,807 | D | — | — | (F3) This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024. (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. (F2) Includes 42,966 unvested RSUs. |
| 2 | Common | Common Stock | 2025-01-06 | A | A | 10,100 | $0.00 | 69,828 | D | — | — | (F1) Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2025, as to 1/3 of the shares underlying the RSUs on January 6, 2026 and as to the final 1/3 of shares underlying the RSUs on January 6, 2027. (F2) Includes 42,966 unvested RSUs. |
| 3 | Derivative | Stock Option (right to buy) | 2025-01-06 | A | A | 45,200 | $0.00 | 45,200 | D | $7.53 · — to 2035-01-05 | 45,200 Common Stock | (F5) This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer. |